trends in PHARMACOLOGICAL SCIENCES

including TOXICOLOGICAL SCIENCES

Author Index

Subject Index

Books Reviewed

1995

Vol 16
Issues 1–12

ISSN 0165 6147

Trends in Pharmacological Sciences

Elsevier Trends Journals
68 Hills Road
Cambridge
UK CB2 1LA
Tel: +44 1223 315961
Fax: +44 1223 464430
+44 1223 321410

Advisory Editorial Board

P. M. Beart, Monash University, Melbourne, Australia
N. J. M. Birdall, National Institute of Medical Research, London, UK
N. G. Bowery, School of Pharmacy, London, UK
J. N. Crawley, National Institute of Mental Health, Bethesda, MD, USA
A. C. Cuello, McGill University, Montreal, Canada
J. R. Fozard, Sandoz, Basel, Switzerland
B. B. Fredholm, Karolinska Institute, Stockholm, Sweden
T. Godfraind, Université Catholique de Louvain, Louvain, Belgium
J. W. Hadden, USF Medical Center, Tampa, FL, USA
J. Hughes, Parke-Davis, Cambridge, UK
M. Lazdunski, CNRS Université de Nice, Valbonne, France
P. Leff, Astra, Loughborough, UK
L. Limbird, Vanderbilt University, Nashville, TN, USA
J. Meldolesi, Instituto H. San Raffaele, Milan, Italy
M. Otsuka, Tokyo Medical & Dental University, Tokyo, Japan
M. M. Reidenberg, Cornell Medical Center, New York, NY, USA
R. Ruffolo, Jr, SmithKline Beecham, King of Prussia, PA, USA
H. Timmerman, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
Z. G. Wang, Institute of Basic Medical Sciences, Beijing, China

Editor **Deborah Girdlestone**

Assistant Editor **Ian Wright**

Editorial Administrator **Anne Ward**

Publisher **Peter Desmond**

Copyright © 1996 Elsevier Science Ltd. All rights reserved.

This journal and the individual contributions contained in it are protected by the copyright of Elsevier Science Ltd. Except as outlined in the terms and conditions, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the publisher, Elsevier Trends Journals, 68 Hills Road, Cambridge, UK CB2 1LA.

Author Index

BR Book Review
L Letter
SR Software Review

A

Anderson, G. P. and Coyle, A., Anderson and Coyle reply (L) 37
Anderson, G. P., *Dictionary of Cytokines* (BR) 213
Angus, J. A., *see* Lew, M. J. 328

B

Barlow, R. B., The use of an antagonist for estimating the degree of agonist stimulation during physiological release 262
Barlow, R. B., *Mathematical Modeling of Pharmacokinetic Data* (BR) 323
Barlow, R. B., *Pharmacokinetic and Pharmacodynamic Data Analysis* (BR) 143
Battistini, B., Botting, R. and Warner, T. D., Endothelins: a knockout in London 217
Baxter, G. S., Kennett, G., Blaney, F. and Blackburn, T. P., 5-HT_2 receptor subtypes: a family re-united? 105
Baxter, G. S. and Tilford, N. S., Endogenous ligands and inverse agonism 258
Beart, P. M. and de Vries, D., Fishing for drugs from the sea: status and strategies 275
Belelli, D., *see* Lambert, J. J. 295
Bell, G. I., *see* Hoyer, D. 86
Ben-Ari, Y., *see* Gozlan, H. 368
Benzi, G., The European Medicines Evaluation Agency: role of experts in drug assessment 409
Berelowitz, M., *see* Hoyer, D. 86
Bicknell, R., *see* Fan, T-P. D. 57
Bill, D. J., *see* Dourish, C. T. (L) 260
Blackburn, T. P., *see* Baxter, G. S. 105
Blaney, F., *see* Baxter, G. S. 105
Blier, P. and de Montigny, C., Blier and de Montigny reply (L) 17
Boarder, M. R., Weisman, G. A., Turner, J. T. and Wilkinson, G. F., G protein-coupled P_2 purinoceptors: from molecular biology to functional responses 133
Bockaert, J., *see* Eglen, R. M. 391
Bond, R. A., *see* Milligan, G. 10
Botting, R., *see* Battistini, B. 217
Bowen, W. P. and Jerman, J. C., Nonlinear regression using spreadsheets 413
Bowman, W. C., *see* Paoletti, R. 150
Breckenridge, A. M., *Pharmacodynamics and Drug Development* (BR) 174
Brenneman, D. E., *see* Lipton, S. A. (L) 122
Brichard, S. M. and Henquin, J-C., The role of vanadium in the management of diabetes 265
Brien, J. F., *see* Nakatsu, K. (L) 293
Bristow, L. J., *see* Seabrook, G. R. (L) 406
Butler, A. R., Flitney, F. W. and Williams, D. L. H., Butler *et al.* reply (L) 293
Butler, A. R., Flitney, F. W. and Williams, D. L. H., NO, nitrosonium ions, nitroxide ions, nitrosothiols and iron-nitrosyls in biology: a chemist's perspective 18

C

Cardinaud, B., *see* Vernier, P. 375
Cattabeni, F., *see* Paoletti, R. 150
Champeil, P., *see* Swillens, S. (L) 405
Champeil, P., *see* Swillens, S. 151
Chan, K., Progress in traditional Chinese medicine 182
Chatelain, P., *see* Spedding, M. 139
Chen, Q., *see* van Breemen, C. 98
Chidiac, P., Receptor state and ligand efficacy (L) 83
Cocks, T. M., *see* Garland, C. J. 23
Cook, N. S., *see* Shaw, L. A. 401
Coyle, A., *see* Anderson, G. P. (L) 37
Cross, A. J., *see* Hunter, A. J. 123

D

Dawson, G. R. and Tricklebank, M. D., Dawson and Tricklebank reply (L) 261
Dawson, G. R. and Tricklebank, M. D., Use of the elevated plus maze in the search for novel anxiolytic agents 33
de Montigny, C., *see* Blier, P. (L) 17
de Vries, D., *see* Beart, P. M. 275
Doble, A., *Searching for Magic Bullets* (BR) 214
Donné-Op den Kelder, G. M., *see* Nederkoorn, P. H. J. 156
Dourish, C. T., Grewal, S. S., Shepherd, J. K., Stanhope, K. J. and Bill, D. J., Benefits of ethological analysis of behaviour (L) 260
Dubocovich, M. L., Melatonin receptors: are there multiple subtypes? 50
Dumuis, A., *see* Eglen, R. M. 391

E

Edvinsson, L., Experimental headache models in animals and humans 5
Eglen, R. M., Wong, E. H. F., Dumuis, A. and Bockaert, J., Central 5-HT_4 receptors 391
Epelbaum, J., *see* Hoyer, D. 86
Europe-Finner, G. N., *see* López Bernal, A. 129

F

Fairlie, D. P., *see* West, M. L. 67
Fan, T-P. D., Jaggar, R. and Bicknell, R., Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy 57
Feniuk, W., *see* Hoyer, D. 86
Fernandez-Salguero, P., *see* Gonzalez, F. 325
Flitney, F. W., *see* Butler, A. R. (L) 293
Flitney, F. W., *see* Butler, A. R. 18

G

Gardner, B., Molecular mechanisms of agonism (L) 259
Garland, C. J., Plane, F., Kemp, B. K. and Cocks, T. M., Endothelium-dependent hyperpolarization: a role in the control of vascular tone 23
Gibb, A., *Patch-Clamp Applications and Protocols. Neuromethods Vol. 26* (BR) 360
Gil, D. W., *see* Pierce, K. L. 253
Girdlestone, D., *see* Watson, S. P. 15
Glowinski, J., The 'septide-sensitive' tachykinin receptor: still an enigma 365
Godfraind, T. and Govoni, S., Recent advances in the pharmacology of Ca^{2+} and K^+ channels 1
Gonzalez, F. and Fernandez-Salguero, P., Diagnostic analysis, clinical importance and molecular basis for dihydropyrimidine dehydrogenase deficiency 325
Govoni, S., *see* Godfraind, T. 1
Gozlan, H. and Ben-Ari, Y., NMDA receptor redox sites: are they targets for selective neuronal protection? 368
Green, A. R., *see* Hunter, A. J. 123
Green, S. M. and Marshall, G. R., 3D-QSAR: a current perspective 285
Grewal, S. S., *see* Dourish, C. T. (L) 260
Grundemar, L., Risks in combination therapy of antidepressant drugs (L) 17

H

Hagan, R. M. and Oakley, N. R., Melatonin comes of age? 81
Harmar, A. J., *Neuropeptide Gene Expression* (BR) 214
Hay, D. W. P., Torphy, T. J. and Undem, B., Cysteinyl leukotrienes in asthma: old mediators up to new tricks 304
Hellewell, P. G., *see* Teixeira, M. M. 418
Hen, R., *see* Lucas, J. J. 246
Henley, J. M., *The Metabotropic Glutamate Receptors* (BR) 78
Henquin, J-C., *see* Brichard, S. M. 265
Hill-Venning, C., *see* Lambert, J. J. 295
Hong, J-S., *see* Pennypacker, K. R. 317
Hoyer, D., Bell, G. I., Berelowitz, M., Epelbaum, J., Feniuk, W., Humphrey, P. P. A., O'Carroll, A-M., Patel, Y. C., Schonbrunn, A., Taylor, J. E. and Reisine, T., Classification and nomenclature of somatostatin receptors 86
Humphrey, P. P. A., *see* Hoyer, D. 86

Humphries, R. G., Robertson, M. J. and Leff, P., A novel series of P_{2T} purinoceptor antagonists: definition of the role of ADP in arterial thrombosis 179
Hunter, A. J., Green, A. R. and Cross, A. J., Animal models of acute ischaemic stroke: can they predict clinically successful neuroprotective drugs? 123
Hutson, P. H., *see* Seabrook, G. R. (L) 406

J
Jaggar, R., *see* Fan, T-P. D. 57
Jarrott, B. and Williams, D., The IUPHAR teaching site on the World Wide Web 294
Jefferys, D. B., The new pharmaceutical regulatory procedures for Europe 226
Jerman, J. C., *see* Bowen, W. P. 413
Jones, T., *see* Ritter, J. M. 117

K
Katori, M., *see* Majima, M. 239
Kemp, B. K., *see* Garland, C. J. 23
Kenakin, T. P., Agonist–receptor efficacy I: mechanisms of efficacy and receptor promiscuity 188
Kenakin, T. P., Agonist–receptor efficacy II: agonist trafficking of receptor signals 232
Kenakin, T. P., Kenakin replies (L) 84
Kenakin, T. P., Pharmacological Proteus? 256
Kennedy, C. and Leff, P., How should P_{2X} purinoceptors be classified pharmacologically? 168
Kennett, G., *see* Baxter, G. S. 105
Kenny, B. A., *see* Spedding, M. 139
Kermode, J. C., Detection of receptor subtypes in radioligand binding studies (L) 405
Kilfeather, S., *see* Tyrrell, D. J. 198
Kitchen, I., *Neglected Factors in Pharmacology and Neuroscience Research* (BR) 281
Knox, A. J. and Peckham, D. G., Na^+ in cystic fibrosis: is it important? 120
Kruk, Z. L. and O'Connor, J. J., Fast electrochemical studies in isolated tissues 145
Kruk, Z. L., *Voltammetric Methods in Brain Systems. Neuromethods Vol. 27* (BR) 361

L
Laduron, P. M., Functional consequences of retrograde axonal transport of receptor-bound neurotensin 338
Laher, I., *see* van Breemen, C. 98
Laissue, J. A., *see* Reubi, J-C. 110
Lambert, J. J., Belelli, D., Hill-Venning, C. and Peters, J. A., Neurosteroids and $GABA_A$ receptor function 295
Lee, M., *see* Milligan, G. 10
Leff, P., Inverse agonism: theory and practice 256
Leff, P., *see* Humphries, R. G. 179
Leff, P., *see* Kennedy, C. 168
Leff, P., The two-state model of receptor activation 89
Lew, M. J. and Angus, J. A., Analysis of competitive agonist–antagonist interactions by nonlinear regression 328
Lipton, S. A., Brenneman, D. E., Silverstein, F. S., Masliah, E. and Mucke, L., gp120 and neurotoxicity *in vivo* (L) 122
López Bernal, A., Europe-Finner, G. N., Phaneuf, S. and Watson, S. P., Preterm labour: a pharmacological challenge 129
Lucas, J. J. and Hen, R., New players in the 5-HT receptor field: genes and knockouts 246

M
MacDonald, J. F., *see* Mody, I. 356
Maggirwar, S. B., *see* Ramkumar, V. 283
Majima, M. and Katori, M., Approaches to the development of novel antihypertensive drugs: crucial role of renal kallikrein–kinin system 239
Marks, G. S., *see* Nakatsu, K. (L) 293
Marshall, G. R., *see* Green, S. M. 285
Masliah, E., *see* Lipton, S. A. (L) 122
Matfield, M., *Handbook of Laboratory Animal Management and Welfare* (BR) 174
McGarry, S. J., *see* Sitsapesan, R. 386
McMillian, M. K., *see* Pennypacker, K. R. 317
Meldrum, B. S., *see* Taylor, C. P. 309
Mikala, G., *see* Varadi, G. 43
Milligan, G., Bond, R. A. and Lee, M., Inverse agonism: pharmacological curiosity or potential therapeutic strategy? 10
Mills, A., *Discovering New Medicines* (BR) 116
Mody, I. and MacDonald, J. F., NMDA receptor-dependent excitotoxicity: the role of intracellular Ca^{2+} release 356
Mori, Y., *see* Varadi, G. 43
Morley, P., *see* Whitfield, J. F. 382
Morton, I. K. M., *The Tachykinin Receptors* (BR) 31
Mucke, L., *see* Lipton, S. A. (L) 122

N
Nahmias, C. and Strosberg, A. D., The angiotensin AT_2 receptor: searching for signal-transduction pathways and physiological function 223
Nakatsu, K., Marks, G. S. and Brien, J. F., Nomenclature of nitrogen oxide-containing molecules (L) 293
Nederkoorn, P. H. J., Timmerman, H. and Donné-Op den Kelder, G. M., Does the ternary complex act as a secondary proton pump and a GTP synthase? 156
Nie, Z., *see* Ramkumar, V. 283

O
O'Carroll, A-M., *see* Hoyer, D. 86
O'Connor, J. J., *see* Kruk, Z. L. 145
Oakley, N. R., *see* Hagan, R. M. 81
Olsen, R. W., *see* Smith, G. B. 162

P
Page, C. P., *see* Tyrrell, D. J. 198
Paoletti, R., Cattabeni, F. and Bowman, W. C., Welcome to the First European Congress of Pharmacology 150
Parratt, J. R. and Szekeres, L., Delayed protection of the heart against ischaemia 351
Pasternak, G. W. and Standifer, K. M., Mapping of opioid receptors using antisense oligodeoxynucleotides: correlating their molecular biology and pharmacology 344
Patel, S., *see* Seabrook, G. R. (L) 406
Patel, Y. C., *see* Hoyer, D. 86
Peckham, D. G., *see* Knox, A. J. 120
Pennypacker, K. R., Hong, J-S. and McMillian, M. K., Prolonged expression of Fos-related antigens: implications for neuronal plasticity 317
Peters, J. A., *see* Lambert, J. J. 295
Phaneuf, S., *see* López Bernal, A. 129
Philippe, H., *see* Vernier, P. 375
Pierce, K. L., Gil, D. W., Woodward, D. F. and Regan, J. W., Cloning of human prostanoid receptors 253
Plane, F., *see* Garland, C. J. 23
Poyner, D., Pharmacology of receptors for calcitonin gene-related peptide and amylin 428
Proška, J., *see* Tuček, S. 205

R
Ragan, C. I., *see* Seabrook, G. R. (L) 406
Ramkumar, V., Nie, Z., Rybak, L. P. and Maggirwar, S. B., Adenosine, antioxidant enzymes and cytoprotection 283
Regan, J. W., *see* Pierce, K. L. 253
Reisine, T., *see* Hoyer, D. 86
Reubi, J-C. and Laissue, J. A., Multiple actions of somatostatin in neoplastic disease 110
Ritter, J., *Clinical Pharmacy and Therapeutics* (BR) 76
Ritter, J. M. and Jones, T., PET: a symposium highlighting its clinical and pharmacological potential 117
Robertson, M. J., *see* Humphries, R. G. 179
Rudin, M., *see* Shaw, L. A. 401
Rybak, L. P., *see* Ramkumar, V. 283

S
Savelkoul, H. F. J., *see* van Oosterhout, A. J. M. (L) 37
Schonbrunn, A., *see* Hoyer, D. 86
Schwartz, A., *see* Varadi, G. 43
Schwartz, J-C. and Sokoloff, P., Schwartz and Sokoloff reply (L) 407
Schwartz, J-C., *see* Sokoloff, P. 270
Schwartz, T. W., *Receptor Molecular Biology* (BR) 322
Seabrook, G. R., Patel, S., Hutson, P. H., Ragan, C. I. and Bristow, L. J., Functional relevance of dopamine receptors (L) 406
Shaw, L. A., Rudin, M. and Cook, N. S., Pharmacological inhibition of restenosis: learning from experience 401
Shepherd, J. K., *see* Dourish, C. T. (L) 260
Sheridan, R. D., Selectivity of the neuroprotective agent lifarizine (L) 292
Silverstein, F. S., *see* Lipton, S. A. (L) 122
Sitsapesan, R., McGarry, S. J. and Williams, A. J., Cyclic ADP-ribose, the ryanodine receptor and Ca^{2+} release 386
Smith, G. B. and Olsen, R. W., Functional domains of $GABA_A$ receptors 162
Sokoloff, P. and Schwartz, J-C., Novel dopamine receptors half a decade later 270
Sokoloff, P., *see* Schwartz, J-C. (L) 407
Spedding, M., Kenny, B. A. and Chatelain, P., New drug binding sites in Ca^{2+} channels 139
Spedding, M., Spedding replies (L) 292
Spivak, C. E., Correlations among Hill parameters reflect models of activating ligand-gated ion channels 39
Standifer, K. M., *see* Pasternak, G. W. 344
Stanhope, K. J., *see* Dourish, C. T. (L) 260
Strosberg, A. D., *Beta$_3$-Adrenergic Agonism: A New Concept in Human Pharmacotherapy* (BR) 175
Strosberg, A. D., *see* Nahmias, C. 223
Swillens, S., Waelbroeck, M. and Champeil, P., Does a radiolabelled ligand bind to a homogeneous population of non-interacting receptor sites? 151
Swillens, S., Waelbroeck, M. and Champeil, P., Swillens *et al.* reply (L) 405
Szekeres, L., *see* Parratt, J. R. 351

T
Taylor, C. P. and Meldrum, B. S., Na^+ channels as targets for neuroprotective drugs 309
Taylor, J. E., *see* Hoyer, D. 86

Teixeira, M. M., Williams, T. J. and Hellewell, P. G., Mechanisms and pharmacological manipulation of eosinophil accumulation *in vivo* 418
Testa, B., *QSAR: Hansch Analysis and Related Approaches* (BR) 280
Tilford, N. S., *see* Baxter, G. S. 258
Timmerman, H., *see* Nederkoorn, P. H. J. 156
Torphy, T. J., *see* Hay, D. W. P. 304
Tricklebank, M. D., *see* Dawson, G. R. (L) 261
Tricklebank, M. D., *see* Dawson, G. R. 33
Tuček, S. and Proška, J., Allosteric modulation of muscarinic acetylcholine receptors 205
Turner, J. T., *see* Boarder, M. R. 133
Tyrrell, D. J., Kilfeather, S. and Page, C. P., Therapeutic uses of heparin beyond its traditional role as an anticoagulant 198

U

Undem, B., *see* Hay, D. W. P. 304

V

Valdenaire, O., *see* Vernier, P. 375
van Breemen, C., Chen, Q. and Laher, I., Superficial buffer barrier function of smooth muscle sarcoplasmic reticulum 98
van Oosterhout, A. J. M. and Savelkoul, H. F. J., Interleukin 5 as a drug target in allergy and asthma (L) 37
Varadi, G., Mori, Y., Mikala, G. and Schwartz, A., Molecular determinants of Ca^{2+} channel function and drug action 43
Vasar, E., *Stress: From Synapse to Syndrome* (BR) 280
Vernier, P., Cardinaud, B., Valdenaire, O., Philippe, H. and Vincent, J-D., An evolutionary view of drug–receptor interaction: the bioamine receptor family 375
Vincent, J-D., *see* Vernier, P. 375

W

Waelbroeck, M., *see* Swillens, S. (L) 405
Waelbroeck, M., *see* Swillens, S. 151
Wahlestedt, C., *PCR in Neuroscience* (BR) 360
Walker, A., *Herbs of Choice: the Therapeutic Use of Phytomedicinals* (BR) 76
Warner, T. D., *see* Battistini, B. 217
Watson, S. P. and Girdlestone, D., *TiPS* on nomenclature 15
Watson, S. P., *see* López Bernal, A. 129
Weisman, G. A., *see* Boarder, M. R. 133
West, M. L. and Fairlie, D. P., Targeting HIV-1 protease: a test of drug-design methodologies 67
Whitfield, J. F. and Morley, P., Small bone-building fragments of parathyroid hormone: new therapeutic agents for osteoporosis 382
Wilckens, T., Glucocorticoids and immune function: physiological relevance and pathogenic potential of hormonal dysfunction 193
Wilkinson, G. F., *see* Boarder, M. R. 133
Williams, A. J., *see* Sitsapesan, R. 386
Williams, D., *see* Jarrott, B. 294
Williams, D. L. H., *see* Butler, A. R. 18
Williams, D. L. H., *see* Butler, A. R. (L) 293
Williams, T. J., *see* Teixeira, M. M. 418
Wong, E. H. F., *see* Eglen, R. M. 391
Woodward, D. F., *see* Pierce, K. L. 253

Z

Zeelen, F. J., *The Lock-and-Key Principle* (BR) 322

Subject Index

compiled by Laurence Errington

A
A80987 70
A84538 70
AC187 425, 426, 426–427
ACE inhibitors, *see* Angiotensin-converting enzyme inhibitors
Acetylcholine
  5-HT_4 receptors and release of 394
  in smooth muscle hyperpolarization 23–28
Acetylcholine receptors, muscarinic
  allosteric modulation 205–213
  evolution 379
N-Acetyl-5-methoxytryptamine, *see* Melatonin
N-Acetyltryptamine 55
Aconitase, NO effects 21
Active site lattice technique, hypothetical (HASL) 289–290
Adenosine
  cytoprotection and antioxidant enzymes and 283–285
  nucleotides containing, *see* ADP; AMP; ATP
Adenylate cyclase,
  P_2 purinoceptors and 136–137, 138
Adenylate cyclase-stimulating fragments of parathyroid hormone in osteoporosis therapy, small 382–386
Adhesion molecules, cell, eosinophil accumulation in allergic inflammation and 418–419, 420–421
Adipocytes, vanadium effects 265, 265–266
ADP
  arterial thrombosis and 179–181
  P_2 purinoceptors and 133, 138, 179
cADP-ribose-induced Ca^{2+} release 386–391
Adrenal medulla, *Fos*-related antigen expression 319–320
Adrenoceptor(s) (in general)
  constitutive expression 11–12
  evolutionary aspects 377, 378, 379
  uterine contractility and 130
β-Adrenoceptor, inverse agonists 11
$β_3$-Adrenoceptor agonists 175–176 (BR)
Adrenomedullin 427–428
AG1132 72
AG1343 72
Age-related sleep disorders and melatonin 82–83
AGM1470 60–61
Agonists 95–97, 188–192, 232–238, 259–260 (L)
  antagonist interactions with, competitive, analysis by nonlinear regression 328–337
  antagonists in estimation of degree of stimulation by 262–264
  antagonists in selective block of 235–238
  efficacy/potency (in general) 188–192, 232–238, 259–260
    nature 188–192
    reversal 235
  inverse, *see* Inverse agonists
  inverse agonist interactions with 92–93
  molecular mechanisms of agonism 259–260 (L)
  pleiotropic response to 233
  quantitative analysis of action 95–97
  receptor classification using 93–94
  receptor conformation and 10, 188–189, 259–260
  trafficking 232–238
    implications 238
  see also specific (types of) agonists
Airways
  cysteinyl leukotriene effects 304–309
  P_2 purinoceptors in epithelia 137
  see also Lung
Alcuronium, allosteric effects at muscarinic acetylcholine receptors 206–207, 210
Algae, excitatory amino acids derived from 277–278
Allergy 418–423
  eosinophils and 418–423
  IL-4 vs. IL-5 as drug target in 37–38 (L)
Allosteric modulation of muscarinic acetylcholine receptors 205–213
α1 subunit of Ca^{2+} channel 43, 45–46
  Ca^{2+} channel blocker binding sites on 48–49
  functional domains 45–46
  interaction with β subunit 45, 45–46
α2 subunit of Ca^{2+} channel 43, 45
Alphaxalone 295
Alzheimer's disease, 5-HT_4 receptor antagonist binding 396
2-Amidotetralins 55
Amiloride in cystic fibrosis 120–121
Amino acids, excitatory, algae containing 277–278
γ-Aminobutyric acid (GABA) receptor mutations, characterization 41
cAMP (cyclic AMP)
  eosinophil accumulation and 422
  P_2 purinoceptors and 136, 138
Amperometric studies 146–147
Amylin receptors 424–428
Amyotrophic lateral sclerosis, Na^+ channel blockers in 314–315
Angiogenesis 57–66
  in cancer 57, 58–59, 113
  inhibitors, *see* Anti-angiogenic substances
Angiogenic factors/growth factors/peptides 57
  agents interfering with production/activity 62–63
  receptors for
    antagonists 62–63
    soluble 63
Angiostatin, metastases inhibited by 64
Angiotensin, type 2 receptor for (AT_2) 223–225
  gene 223, 225
Angiotensin II, hypertension induced in BN-Ka rat by 239–240
Angiotensin-converting enzyme inhibitors 401–402
  calcium antagonists and, synergistic effects 2, 3
  coronary artery restenosis and effects of 401–402
  in hypertension 2, 244
  in renal failure 3
Animals
  handbook of management and welfare in laboratory 174 (BR)
  models, *see* Models
  species, *see* Species
Annual Review of Medicine (Vol. 46), selected topics in the Clinical Sciences, 362 (BR)
Annual Review of Neuroscience (Vol. 18) 216 (BR)
Annual Review of Pharmacology and Toxicology (Vol. 35) 282 (BR)
Annual Review of Physiology (Vol. 57) 215–216 (BR)
Anorectic actions of vanadium 268–269
Antagonists
  agonists and effects of, *see* Agonists
  competitive, two-state model of receptor activation and 92
  dissociation constant, estimation by non-linear regression method 328–337
  negative, *see* Inverse agonists
  receptor classification using 93–94
  receptor conformation and 10
  see also specific (types of) antagonists
Anti-angiogenic substances 59–66
  combination therapy 65
  side-effects/toxicity 65
  strategies of therapy 65–66
  types 60–61
Antibiotics, anti-angiogenic 60
Antibodies, monoclonal, *see* Monoclonal antibodies
Anticancer (antitumour) therapies 58–59, 64, 113–115, 200
  PET studies 119
  vascular targeted gene therapy 58–59
Anticonvulsants
  Na^+ channel blockers 312
  neurosteroids as 301–302
Antidepressant drugs, risk of combination therapy 17 (L)
Antihypertensives 3, 239–246
  novel 239–246
    approaches to developing 245
Antioxidant enzymes, adenosine effects 283–285
Antiplatelet agents in coronary artery restenosis prevention 403
Antipsychotic drugs (neuroleptics)
  D_3 receptor targets 274, 405 (L), 406 (L)
  D_4 receptor targets 274
  5-HT_2 receptor agonists/antagonists as 108
Antisense agents (oligonucleotides) 344–350
  anti-angiogenic 62

5-HT receptor knockout with opioid receptor mapping employing 250, 344–350
Antithrombotic compounds
in coronary artery restenosis prevention 403
novel 179–181
Antitumour therapies, *see* Anticancer therapies
Antiviral activities of protease inhibitors, *in vitro* 69
Anxiety
elevated plus maze model 33–37, 260–261 (L)
5-HT_2 receptor agonists/antagonists and 108
5-HT_4 receptor antagonists and 395
AP-1 transcription factors 317–321
Apoptosis in endothelium, targeted cancer gene therapy inducing 58
Appetite disorders, 5-HT_2 receptor agonists/antagonists and 108
Arteries
'resistance', endothelium-derived hyperpolarizing factor studies 28
small, endothelium-derived hyperpolarizing factor studies 27–28
thrombosis, ADP and 179–181
see also specific arteries
Arteriovenous shunting, cranial, migraine and 9
Ascorbic acid as redox regulator of NMDA receptors 370
Asthma
cysteinyl leukotrienes in pathogenesis of 304–309
IL-4 vs. IL-5 as drug target in 37–38 (L)
phosphodiesterase inhibitors in 422
AT_2 receptors, *see* Angiotensin, type 2 receptor
Atherosclerosis
angiogenesis and 57–58
endothelial-dependent relaxation and vasodilation in coronary arteries and 29
ATP
P_2 purinoceptors and 133, 138, 168–173
ryanodine receptor-sensitive Ca^{2+} channels and 387, 389
synthesis, proton transport and 157, 158
see also α,β-MethyleneATP; 2-MethylthioATP
ATP synthase as secondary proton pump 158
Automated data analysis in nonlinear regression studies 416–417
Autonomic nervous system, cysteinyl leukotrienes effect 306–307
Autoreceptors
dopamine, release-regulating 145–146
5-HT, release-regulating 145–146
Axonal transport of receptor-bound neurotensin, functional consequences of retrograde 338–343

B

Bacterial endotoxin, delayed cardioprotection by 354
Bacteriorhodopsin as primary proton pump 158
Ball and Stick 429 (SR)
Balloon dilatation of coronary artery, *see* Coronary angioplasty
Behaviour
in elevated plus maze, analysis 34, 260–261 (L)
ethological analysis, *see* Ethological models
5-HT_4 receptors and 394–396
Benzodiazepine binding site/domains, $GABA_A$ receptor 164, 165–166, 167
β-Adrenoceptors, *see* Adrenoceptors
β subunit of Ca^{2+} channel 43, 45, 45–46
interaction with α1 subunit 45, 45–46
BIMU1 and BIMU8 and 5-HT_4 receptors 394
Bioamine receptor family, evolutionary view of drug interactions with 375–381
see also Monoamines
Biodiversity, marine organism-derived products and importance of 278–279
Bioenergetics, proton pumping in 157
Biotechnology, Language of (Dictionary of Terms) 429 (BR)
Bladder of rat, new tachykinin receptor 365–366
Blood
flow, cerebral, *see* Brain
pressure, elevated, *see* Antihypertensives; Hypertension
Blood vessels, *see* Angiogenesis; Angiogenic factors; Arteries; Cardiovascular system; Endothelium; Microvasculature; Smooth muscle; Tone; Venules and *specific conditions/diseases/vessels and entries above/below*
BN-Ka rat model of hypertension 239–240, 243
Bone-building fragments of parathyroid hormone in osteoporosis therapy, small 382–386
Bootstrapping data for estimating pK_b values for antagonists 328–337
BQ123 221
Bradykinin
degradation 243, 245
effects 240
Brain/cerebrum
axonal transport of receptor-bound neurotensin, retrograde 339–340
blood flow
inadequate, *see* Ischaemia
PET in measurement of 117
fast electrochemical studies 145–149
Fos-related antigen expression 317–321
5-HT autoreceptors 145–146
5-HT_2 receptors 108
5-HT_4 receptors 246–247, 391–398
agonists for 391, 392, 394–395, 396
antagonists for 391, 392, 393
NMDA receptors, *see* NMDA receptors
trauma, *see* Injury
voltammetric studies, *see* Voltammetry
see also Central nervous system
Bronchodilators, cysteinyl leukotriene receptor antagonists as 307
Brown-Norway-Katholiek (BN-Ka) rat model of hypertension 239–240, 243
Buffer barrier, superficial, smooth muscle sarcoplasmic reticulum as 98–105
BW723C86 106–107

C

CA1 region, NMDA receptors in, redox modulation 369
Caffeine and ryanodine receptor-sensitive Ca^{2+} channels 387
Calcitonin gene-related peptide 424–428
headache/migraine and 5, 9
pharmacology 424–425
receptors 424–428
antagonists 425–427
structure of, and its homologues 424
Calcium ion(s) 1–4, 98–105
cyclic ADP-ribose-induced release 386–391
homeostasis 1, 3–4
neuronal transport, neuronal protection and toxicity mechanisms related to 315, 356–359, 372
NMDA receptors and 372
and P_2 purinoceptors 171
intracellular 136
in superficial smooth muscle sarcoplasmic reticulum, transport 98–105
Calcium ion channel(s) 1–4, 43–49, 139–142
agonists, muscle contraction/sarcoplasmic reticulum and effects of various 100–101
antagonists, *see* Calcium ion channel antagonists
biochemical characterization 43
blockers, *see* Calcium ion channel antagonists
chimeric 48–49
genes 43–45
functional implications of expressed 44–45
in hypertension 2
molecular determinants of function and drug action 43–49
ryanodine receptor-sensitive 386–391
subunits 43–49
Ca^{2+} channel blocker binding sites on 48–49
pathophysiological aspects 47–48
see also specific subunits
Calcium ion channel antagonists (channel blockers) 139–142
ACE inhibitors and, synergistic effects 2, 3
binding sites for
on α1 subunit 48–49
for new drugs 139–142
in cardiovascular disease 2, 3
in cerebrovascular disease 141–142
in renal failure 3
Calcium ion-dependent K^+ channels and NO 26–27
Calmodulin and ryanodine receptor-sensitive Ca^{2+} channels 387
Cancer 58–59, 110–115
metastases, *see* Metastases
PET applications 119
somatostatin effects 110–115
therapies, *see* Anticancer therapy
vascular system in 64, 112–113
growth (angiogenesis) 57, 58–59, 113
see also Tumours
Carbon fibre electrodes in fast cyclic voltammetry 148–149
Carcinoma, colonic, somatostatin effects on vascular system of 112–113
Cardiovascular system
disease
angiogenesis and 57–58
Ca^{2+} channels and antagonists in 2
K^+ channels and 3
fantofarone effects 140
see also Heart
Carotid artery occlusion model of ischaemia 124, 126
Catecholamines, delayed myocardial protection using 352
Cell adhesion molecules, eosinophil accumulation in allergic inflammation and 418–419, 420–421
Central nervous system
Fos-related antigen expression 317–321
HIV gp120-related damage 122
5-HT autoreceptors 145–146
5-HT_2 receptors 105
5-HT_4 receptors 246–247, 391–398
agonists 391, 392, 394–395, 396
antagonists 391, 392, 393
NMDA receptors, *see* NMDA receptors
PET studies 117–118
protection, *see* Neuroprotection
rat 31 (BR)
see also Brain *and other specific regions*
Cerebral artery occlusion models, middle 125, 127
Cerebrovascular accident, *see* Stroke
Cerebrovascular pain pathways in migraine 7–8
Cerebrum, *see* Brain
c-*fos*, *see* Fos; Fos-related antigens

Chemokines/chemoattractants, heparin binding to/effects on 199, 202–203, 203
Chinese medicine, traditional, progress in 182–187
Chloride channels defect in cystic fibrosis 120
m-Chlorophenylpiperazine 107, 108
  preclinical/clinical effects 107, 108
Chromaffin cells, monoamine release 148
Circadian clock 82–83
  age-related disruption 82–83
  melatonin and 81, 82–83
Clock, circadian, *see* Circadian clock
Cluster headache, experimental models 6
Cognition and 5-HT_4 receptors 394–395
Colchicine and axonal transport 342
Colonic carcinoma, somatostatin effects on vascular system of 112–113
CoMFA 286–287, 288
Committee for Propriety Medicinal Products (CPMP) 226–231, 409
Committee for Veterinary Medicinal Products (CVMP) 409
Comparative Molecular Field Analysis (CoMFA) 286–287, 288
Competition
  homologous, in studies of receptor subtype discrimination 376–377 (L)
  spreadsheets in nonlinear regression studies of 414
Competitive antagonists, two-state model of receptor activation and 92
Computer programs, *see* Software programs
Conditioned models of anxiety 35
  advantages and disadvantages 35
Conformation, receptor, *see* Receptor
Contamination of traditional Chinese medicine natural products 186
Contraction, muscle
  Ca^{2+} channel agonist effects 100–101
  uterine/myometrial, premature labour and 129–132
  vascular smooth, P_{2X} purinoceptors and 169
Convulsions, prevention, *see* Anticonvulsants
Coronary angioplasty, percutaneous transluminal (balloon), restenosis following 401–404
  injury by balloon causing restenosis 401, 402, 402–403
Coronary arteries
  angiogenesis in 57–58
  endothelial-dependent relaxation 28–29
  occluded, restenosis of treated 401–404
Cortical-spreading depression 8
Corticosteroid(s), *see* Glucocorticoids; Steroids
Corticosteroid-binding globulin 194
CPD12 and CPD14 61–62, 65
Cranial arteries, vascular receptors related to migraine in 9
Cranial arteriovenous shunting, migraine and 9
Cranial trauma, *see* Injury
Cuello, A. Claudio (Advisory Editorial Board) 14
Curve-fitting spreadsheet module in nonlinear regression studies 413–417
Cyclic nucleotides, *see* ADP; AMP
CYP2D gene 17
Cysteinyl leukotrienes in asthma pathogenesis 304–309
Cystic fibrosis 120–121, 137
  Na^+ transport and 120–121
  P_2 purinoceptors and 137
  therapy 120–121, 137
  transmembrane conductance regulator 120, 137
Cytokines
  dictionary of 213 (BR)
  glucocorticoid effects antagonised by 196
Cytoprotection, adenosine and antioxidant enzymes and 283–285
Cytosine deaminase in cancer gene therapy 58
Cytotoxicity of NO 21

D
D_1–D_5 receptors, *see* Dopamine receptors
Dantrolene, protection from excitotoxicity by 357–358
Data analysis, automated, in nonlinear regression studies 416–417
Decision-making process in mutual recognition systems, pharmaceutical regulatory procedures and 231
Declaration of interests, European Medicines Evaluation Agency's expert transparency and 410–411
Degeneration, neurological
  acute, neuroprotective Na^+ channel blockers in 312–314
  progressive, neuroprotective Na^+ channel blockers in 314–315
δ-opioid receptor gene clone 344
  antisense oligonucleotides to 346–347
δ subunit of Ca^{2+} channel 43, 45
Deoxycorticosterone-salt hypertension 242–243
Depression, cortical/Leao-spreading 8
Depression, psychiatric syndrome of, 5-HT_2 receptor agonists/antagonists and 108
Design, drug
  quantitative analysis of agonist action and 95–96
  structure-based, packages 290
Dexamethasone suppression of IL-6 193
Diabetes and vanadium 265–270
Dictionary of Cytokines 213 (BR)
Dictionary in six languages, medical 78–79 (BR)
Dictionary of Terms in Biotechnology 429 (BR)
Dihydropyridine(s) (with Ca^{2+} channels) 139
  binding 48–49
Dihydropyridine dehydrogenase deficiency 325–327
Diphenylbutylpiperadines 140–142
Diphenylpiperazines 140–142
Dissociation constants (K_A/K_A^*), receptor activation models and 89–97
Disulphides as redox regulators of NMDA receptors 370
5,5′-Dithiobis-2-nitrobenzoic acid (DTNB) and NMDA receptors 368, 373
Dithiothreitol and NMDA receptors 368–369
Dizocilpine as neuroprotective agent 125
DNA
  synthesis, P_2 purinoceptors and 137
  transcription factors, steroid receptors competing for 196
Dopamine, release in brain slices, fast electrochemical studies 145–148, 148, 149
Dopamine receptors 145–146, 270–274, 405–406 (L)
  agonists (in general), *Fos*-related antigen expression regulated by 317–318
  autoreceptors 145–146
  constitutive activity 12
  D_1 12, 271, 272, 379, 380
  D_1-like 271
  D_2 145, 271, 272, 372, 380
  D_2-like 271
  D_3 271, 272, 405–406 (L)
    as antipsychotic drug targets 274, 405 (L), 406 (L)
  D_4 271, 272
    as antipsychotic drug targets 274
  D_5 12, 271, 272
  evolution 379, 380
  novel 270–274, 405–406 (L)
Dopaminergic neurones, retrograde axonal transport of receptor-bound neurotensin 339–340
Drosophila spp., octopamine–tyramine receptor 235

E
Early genes as pain response markers 7
Eating disorders, 5-HT_2 receptor agonists/antagonists and 108
Ebelactone in hypertension 242, 245
Ectonucleotidase inhibitors 170–171
Efficacy
  ligands, *see* Ligands
  traditional Chinese medicine natural products 186–187
Eicosanoids, *see* Prostanoids
Elderly, melatonin and sleep disorders in 82–83
Electrochemical studies in isolated tissues, fast 145–149
Electrophysiological responses in vascular smooth muscle, P_{2X} purinoceptor-mediated 169
Elevated plus maze model of anxiety 33–37, 260–261 (L)
Endocrine system, *see* Hormones
Endoplasmic reticulum, neuronal, Ca^{2+} transport and 356–359
Endothelin (ET) 217–222
  pathophysiology 218–221
  receptors 217–218
    antagonists 218, 220, 221
    evolutionary aspects 379
Endothelin-converting enzymes 217, 219
  inhibitors, development 217
Endothelium (vascular)
  balloon injury to, restenosis of coronary artery due to 402–403
  5-HT_2 receptors 108
  leucocyte interactions with, *see* Leucocyte
  P_2 purinoceptors and platelet interaction with 134–137
  tumour, drug targeting 58–59
  see also Vascular endothelial growth factor
Endothelium-dependent hyperpolarization 3, 23–30
Endothelium-derived hyperpolarizing factor (EDHF) 3, 23–30
  basal release 26
  characteristics of action 25
  functional significance 27–28
  identity 25
  mechanism of action 25–26
Endothelium-derived relaxing factor, *see* Nitric oxide
Endotoxin, delayed cardioprotection by 354
Energy transduction, proton semiconductors and 157–159
Enzymes
  heparin binding to 199
  kinetics, fundamentals 399 (BR)
  see also specific enzymes
Eosinophils 418–423
  accumulation 418–423
    disease and 418
    mechanisms and manipulation 418–423
  in asthma 305–306
Epilepsy/epileptic disorders
  drug treatment, *see* Anticonvulsants
  NMDA receptors redox sites and 373–374
Epithelia, lung, P_2 purinoceptors 137
Epoxyeicosatrienoic acids, endothelium-derived hyperpolarizing factor activity 25
ET receptors, *see* Endothelin
Ethological models (of behaviour) 260–261 (L)
  anxiety 35

European Congress of Pharmacology, first 150
European Medicine Evaluation Agency (EMEA) 226, 227, 228, 409–412
role of experts in drug assessment 409–412
European Union, regulatory procedures and directives for pharmaceuticals 226–231, 409–412
Evolutionary view of drug–receptor interactions 375–381
Excitatory amino acids, algae containing 277–278
Excitotoxicity, NMDA receptor-dependent 356–359
Experimental models, *see* Models
Extracellular matrix proteins, heparin binding to 199
Extracellular space, Ca^{2+} unloading from sarcoplasmic reticulum lumen to 101

F

fa/fa rat 267
Fantofarone 139–140
Fast electrochemical studies in isolated tissues 145–149
Federation of European Pharmacological Sciences, first congress 150
Feeding disorders, 5-HT_2 receptor agonists/antagonists and 108
5-Fluorouracil toxicity and dihydropyridine dehydrogenase deficiency 325–327
Fluspirilene 140–141
Focal cerebral ischaemia models 124
c-Fos and pain responses 7
Fos-related antigens, implications of prolonged expression 317–321
FPL55712 effects 306
in asthma 307
FPL66096 179, 180
FPL67085 179–181
FPL67156 170, 172
Free radicals (including reactive oxygen species)
adenosine and antioxidant enzyme interactions and their effects on 283–285
NO as 18, 371
as redox regulators of NMDA receptors 370–371
Fumagillin (and analogue) 60–61

G

G protein(s) 188–192
uterine contractility and 130–131
G protein-coupled receptors 83–85 (L), 188–192, 232–234, 375–381
agonists at
conformational changes induced by 188, 259–260 (L)
efficacy 188–192
antisense oligonucleotide studies of 349
AT_2 angiotensin receptors as 223
bioamine, evolutionary view of drug interactions with 375–381
constitutive activity 12
5-HT receptors as 248–249
inappropriate/over-expression in disease 12–13
inverse agonists at 256–258, 258
marine organism-derived ligands for 278
models concerning activation of 83–85 (L), 89, 96
opioid receptors as 349
P_2 purinoceptors as 133–139
prostanoid receptors as 253
proton transport and 156–161
GABA, $GABA_A$ receptor binding site 162–163, 167
GABA receptor 162–168
mutations, characterization 41
type A ($GABA_A$) 162–168
functional domains 162–168
neurosteroids and 295–303
Gallamine, allosteric effects at muscarinic acetylcholine receptors 205
γ subunit of Ca^{2+} channel 43
Gancyclovir in cancer gene therapy 58
Gene expression, retrograde axonal transport and 340–341
see also specific genes
Gene targeting/knockout
endothelin 217
5-HT receptors 250–252
Gene therapy
cystic fibrosis 120
vascular targeted
in cancer 58–59
in coronary artery restenosis prevention 403
in ischaemia 59
Generating optimal linear partial least-squares estimations (GOLPE) 288
Gerbil, global ischaemia models 124, 126
Global cerebral ischaemia models 124
Glucocorticoids 193–197
eosinophil accumulation inhibited by 421–422
immune function and 193–197
receptors 194, 194–196, 196
see also Corticosteroid-binding globulin; Steroids
Glucose, metabolism/homeostasis, vanadium effects 265–269
Glucose transporters, vanadium effects 267
Glutamate receptors, metabotropic 78 (BR)
Glutamic acid residues, Ca^{2+} channels 46–47
Glyceryl nitrate in headache model 9
gp120 of HIV, neurotoxicity 122
GR113808 as 5-HT_4 receptor antagonist 391, 392, 393, 396
Growth factors, heparin binding to 199
Growth hormone-inhibiting hormone, *see* Somatostatin
GTP-binding proteins, *see* G protein
GTP synthase, ternary complex (of G protein-coupled receptors) as 156–161
Guanine nucleotide-binding proteins, *see* G protein
Guinea pig
brain, 5-HT_4 receptors 393
ileum, tachykinin receptor, new 365–366

H

H_1 receptor antagonists, eosinophils accumulation inhibited by 420
Hansch analysis in QSAR 280 (BR)
Head trauma, Na^+ channel blockers in 313–314
Headache, experimental models 5–9
Healing of wounds, angiogenesis in 58–59
Heart
coronary disease, restenosis following treatment 401–404
failure, Ca^{2+} antagonists in 2
ischaemia 351–355
Ca^{2+} antagonists in 3
delayed protection against 351–355
K^+ channels and their opening in 3
PET studies 118–119
see also Cardiovascular system
Heat shock proteins, tissue specific expression 196
Helper T cells in allergy and asthma, type 2 (T_H2), drugs targeting 37–38
Heparan sulphate, selectins binding to 200–201
Heparin 198–204
chemical composition/cellular location 198
in non-anticoagulant therapy 198–204
proteins binding to 198–199
Hepatocytes
P_2 purinoceptors 138
vanadium effects 265
Hill parameters and activation ligand-gated ion channels 39–42
Hippocampus
in global ischaemia model 124, 126
NMDA receptors in, redox-modulated 369, 373
Histamine receptor
evolution 379
H_1 antagonists, eosinophils accumulation inhibited by 420
HIV
gp120, neurotoxicity 122
proteases
3D-QSAR 289, 290
targeting 67
Homologous competition studies of receptor subtype discrimination 376–377 (L)
Hormones
immune system and, interactions 193–197
peptide, uterine contractility and 130
tumours dependent on (for growth) 111–112
tumours producing 13
5-HT, *see* 5-Hydroxytryptamine
Human immunodeficiency virus, *see* HIV
Hydrogen-bonded chains, proton transport and 157–159
Hydrogen ion (proton) transport and G protein-coupled receptors 156–161
7-Hydroxy-(di-*n*-propylamino)tetralin (7-OH-DPAT), D_3 receptors and 272, 272–273, 406, 407
11-β-Hydroxysteroid dehydrogenase and glucocorticoid receptors and 196
5-Hydroxytryptamine, methysergide interactions with, nonlinear regression method of analysis 334
5-Hydroxytryptamine receptors 105–110, 246–252, 391–398
antidepressants drugs and 17 (L)
brain, *see* Brain
evolutionary aspects of drug interactions with 376, 378, 379
genetic aspects 250–252
inverse agonists 10
nomenclature/classification 15, 105–110
sequence homologies 106
5-HT_1 248, 379
5-HT_{1A} 376
5-HT_{1B} 376
mutants lacking 250
5-HT_{1D} 248, 376
migraine and 8–9
5-HT_2 105–110, 248–249, 379, 380
agonists 105–107
antagonists 107–108
ligand affinity for 109
subtypes 105–110
5-HT_{2C}, mutants lacking 250–251
5-HT_4 246–247, 391–398
agonists 391, 392, 394–395, 396
antagonists 391, 392, 395, 396
5-HT_5 247, 249
5-HT_6 247–248, 249
5-HT_7 247, 248, 248–250
5-Hydroxytryptamine syndrome 17
Hyperglycaemia, vanadium effects in 267, 268
Hyperkalaemic periodic paralysis and Ca^{2+} channels 47–48
Hyperpolarization, *see* Endothelium
Hypertension 239–246
Ca^{2+} channels and their antagonists in 2
drugs in, *see* Antihypertensives
K^+ channels and their openers in 3
Hyperthermia, malignant, Ca^{2+} channels and 47–48
Hypoglycaemic, vanadium as 267, 268

Hypothalamus, *Fos*-related antigen expression 320
Hypothetical active site lattice (HASL) technique 289–290

I
ICAM-1, eosinophil accumulation in allergic inflammation and 419, 420
Ileum, guinea-pig, new tachykinin receptor 365–366
Immune cell migration in inflammation, heparin effects 200–201, 203–204
Immune system 193–197
  glucocorticoids and 193–197
  somatostatin effects on neoplasms and its effects on 112
Indolizinsulphones 139–140
Infarction, cerebral, photochemically induced 125
Inflammation
  airway, cysteinyl leukotrienes promoting 304
  allergic, eosinophils and 418–423
  heparin effects in 199–200
    immune cell migration and 200–201, 203–204
    therapeutic 204
  neurogenic, plasma extravasation following 7
  peritumoural, somatostatin effects 113
Injury/trauma
  coronary artery caused by balloon 401, 402, 402–403
  cranial/brain
    Fos-related antigen expression 320
    Na^+ channel blockers in 313–314
  spinal, Na^+ channel blockers in 313–314
Inositol(1,4,5)triphosphate and sarcoplasmic reticulum Ca^{2+} unloading 101–103
Insulin
  deficiency, rat model 267
  resistance, rat model 267
  signal transduction pathways 266
  vanadium effects mimicking 265–268
Insulin-like growth factor-1 and tumour growth 111–112
Integrins
  eosinophil accumulation in allergic inflammation and 418
  $\alpha_v\beta_3$, angiogenesis inhibited by monoclonal antibodies to 64
Intercellular adhesion molecule 1 (ICAM-1), eosinophil accumulation in allergic inflammation and 419, 420
Interleukin 4 vs. IL-5 as drug target in allergy and asthma 37–38 (L)
Interleukin 5 and eosinophil accumulation 422
Interleukin 6, dexamethasone suppression of 193
International Union of Pharmacology (IUPHAR)
  receptor nomenclature approved by 16
  teaching site on World Wide Web 294
Internet, IUPHAR teaching site on World Wide Web 294
Inverse agonists (negative antagonists) 10–13, 256–259
  agonist interactions with 92–93
  examples 10–11
  receptor conformation and 10
  therapeutic potential 11–13
2-Iodomelatonin, [^{125}I]-labelled, binding sites 50–53
Ion channels
  $GABA_A$ receptor ligand-gated, *see* Ligand-gated ion channels
  premature labour pharmacotherapy and 132
  see also Multi-ion theory *and specific ions*
Iron–nitrosyls 20–21
Ischaemia
  adenosine and 283
  angiogenesis in 59
  cerebral
    ion channels in 3–4
    lifarizine effects 141
    Na^+ channel blockers in 141, 313, 315
    NMDA receptors redox sites and 373–374
    stroke with, *see* Stroke
  drug management 3, 4
  heart, *see* Heart
  models of 123–125
Isoprenaline, delayed myocardial protection with 352
IUPHAR, *see* International Union of Pharmacology

J
JG365 68

K
Kainate effects on Fos-related antigen expression 319
Kallikrein–kinin system and hypertension 239–246
κ-opioid receptor gene clone 344
  antisense oligonucleotides to 347, 348–349
Kidney
  failure, Ca^{2+} antagonists and ACE inhibitors in 3
  kallikrein–kinin system in, hypertension and 239–246
Kinin, *see* Kallikrein–kinin system; Tachykinin

L
L-selectins and heparin 200, 201
L-type Ca^{2+} channel 43–49
  function and drug action 43–49
  structure 43
Labour, preterm, prevention 129–133
Leao spreading depression 8
Learning and 5-HT_4 receptor signal transduction 393–394
Least-squares method in nonlinear regression 413–414
Leukocytes, vascular endothelium interactions with 418–423
  heparin and related molecules affecting 200, 201, 203
  see also specific types of leucocytes
Leukotriene(s), cysteinyl, in asthma pathogenesis 304–309
Leukotriene receptor antagonists in asthma therapy 305, 307
Lifarizine 292 (L)
  as Ca^{2+} channel blocker 141
  in cerebrovascular disease 141
  as Na^+ channel blocker 141, 292 (L)
Ligand(s), receptor
  affinity 15–16, 90, 91
    definition 90
    dissociation constants estimated via measurement of 95–96
    two-state model of receptor activation and 90, 91
    variations between cells/tissues 91
  allosteric, at muscarinic acetylcholine receptors 205–213
  efficacy 90, 91, 188–192
    definition 91
    dissociation constants estimated via measurement of 95–96
    nature of 188–192
    receptor state and 83–85 (L)
    two-state model of receptor activation and 90, 91
  variations between cells/tissues 91–92
  inverse agonists and endogenous 258–259
  marine organism-derived 277–278
  nomenclature of receptors according to preferred 15–16
  radiolabelled, *see* Radiolabelled ligands
  see also specific ligands
Ligand-gated ion channels 167
  Hill parameters and activation of 39–42
  see also specific ion channels and Neurotransmitter-gated ion channels
Limbic system, 5-HT_4 receptors 391–392
Lipid A derivatives, delayed cardioprotection by 354
5-Lipoxygenase activating protein (FLAP) 304
  inhibitors 305, 307
5-Lipoxygenase inhibitors
  in asthma therapy 305
  eosinophils accumulation inhibited by 420
Liver cells, *see* Hepatocytes
Lock-and-key principle in drug development 322 (BR)
Locomotor activity, anxiety measures and 33–34
Long-term potentiation, NMDA receptor activation and 372–373
Lung
  amylin and CGRP binding sites 427
  cysteinyl leukotrienes released in 304–309
  P_2 purinoceptors in epithelia 137
Lymphatic tissue, somatostatin effects 112
Lymphocytes, T type 2 helper (T_H2), in allergy and asthma, drugs targeting 37–38

M
McNA343 210
Magic bullets, searching for 214–215 (BR)
Magnesium ions and P_{2X} purinoceptors 171
Malignant hyperthermia and Ca^{2+} channels 47–48
Malignant tumours, *see* Cancer
Manganese ions, Ca^{2+} buffering in superficial sarcoplasmic reticulum and movements of 99
Marine-derived drugs 275–279
Maze, elevated plus 33–37, 260–261 (L)
Medical dictionary in six languages 78–79 (BR)
Megacolon, toxic, endothelin 3 deficiency and 217, 218
Melatonin (*N*-acetyl-5-methoxytryptamine) 50–56, 81–83
Melatonin receptors 50–56, 81–83
  agonists 54
    novel 55, 56
  antagonists, novel 55, 56
  molecular structure 55
  subtypes (ML) 50–56, 81–83
    ML_1 53–54, 55, 56, 81
    ML_2 54–55, 56, 81
Membranes, *see also* Transmembrane
Memory and 5-HT_4 receptor signal transduction 393–394
Metabotropic glutamate receptors 78 (BR)
Metastases
  angiostatin inhibition 64
  heparin effects 200
5-Methoxy-*N*-acetyltryptamine analogues 55
5-Methoxycarbonylamino-*N*-acetyltryptamine (5-MCA-NAT) 53, 56
N-Methyl-D-aspartate receptor, *see* NMDA receptor
α,β-MethyleneATP and P_{2X} purinoceptors 168–173
N-Methylscopolamine (NMS) and muscarinic acetylcholine receptors 205–211
2-MethylthioATP and P_{2X} purinoceptors 168–173

Methysergide–5-HT interactions, non linear regression method of analysis 334
Mice, 5-HT_2 receptors 109
Microvasculature/microcirculation
airway, cysteinyl leukotrienes increasing permeability 304–305
systemic, postcapillary venules of, leukocyte accumulation at 418–419
Migraine 5–6, 6–9
5-HT receptors and 8–9, 108
models and mechanisms of 6–9
Minimization algorithm in nonlinear regression 414–415
Mitogenic pathways and P_2 purinoceptors 137
MK571 in asthma 305
Models (of disease), experimental animal and human
anxiety 35
cerebral ischaemia and ischaemic stroke 123–128
coronary artery restenosis 401–402
cystic fibrosis 137
diabetes, vanadium effects 267
endothelin receptor antagonists in various 218–221
headache 5–9
hypertension 239–241, 243
tumour, somatostatin effects 111
Models (theoretical/mathematical)
ion channel activation 39–42
receptor activity/activation 83–85 (L), 89–97
transmitter-gated ion channels 165
Monoamines
receptor family, evolutionary view of drug interactions with 375–381
release from chromaffin and other cells 148
see also specific monoamines
Monoclonal antibodies
angiogenesis-inhibiting 63, 64
eosinophil accumulation-suppressing 420
in vascular targeted cancer gene therapy 59
Monod–Wyman–Changeux model 42, 89
Motor neurone disease, Na^+ channel blockers in 314–315
Mouse, 5-HT_2 receptors 109
μ-opioid receptor gene clone 344
antisense oligonucleotides to 347, 347–348
Mucociliary transport in asthma 306
Mucus secretion, airway, in asthma 306
Multi-ion (multi-occupancy) theory 46
Muscarinic acetylcholine receptors, *see* Acetylcholine receptors
Muscle, *see* Skeletal muscle; Smooth muscle
Mutant receptors
constitutive expression 11–13
$GABA_A$ receptor 165
Hill parameters in characterization of 39, 41
muscarinic acetylcholine receptors 209
Mutual recognition systems, pharmaceutical regulatory procedures and 228, 231
Myocardial ischaemia, *see* Heart
Myometrium and premature labour 129–132

N

β-NAD^+ and ryanodine receptor-sensitive Ca^{2+} channels 390
Natural products
marine sources 275–279
traditional Chinese medicine 182–187
Neointimal thickening, anti-restenosis research and 401–402
Neoplasms, *see* Cancer; Tumour *and specific types*
Nervous system
autonomic, cysteinyl leukotrienes effects 306–307
central, *see* Central nervous system
Neural networks, 3D-QSAR using 287, 288
Neurogenic inflammation, plasma extravasation following 7
Neurokinin (NK) receptors, *see* Tachykinin receptors
Neuroleptics, *see* Antipsychotic drugs
Neurological problems (meaning CNS), *see* Central nervous system
Neuromethods
patch-clamp applications and protocols (Vol. 26) 360–361
voltammetric methods in brain systems (Vol. 27) 361
Neuronal protection, *see* Neuroprotection
Neuropeptide gene expression 214 (BR)
Neuroprotection 309–316
agents aiding 309–316
in ischaemic stroke models 123–128, 141–142
Na^+ channel blockers as 141–142, 292 (L), 309–316
NMDA receptor redox sites as targets for selective 368–374
Neuroscience
Annual Review of (Vol. 18) 216 (BR)
Methods in (Vol. 25), receptor molecular biology 322 (BR)
neglected factors in research 281 (BR)
PCR in 360 (BR)
Neurosteroids, *see* Steroids
Neurotensin, functional consequences of retrograde axonal transport of receptor-bound 338–343
Neurotoxicity 356–359
HIV gp120 122
NMDA receptor-dependent 356–359
Neurotransmitter(s), NMDA receptors modifying release of various 372
Neurotransmitter-gated ion channels
$GABA_A$ receptor 165
redox modulation 369
Neutrophil migration in inflammation, inhibitors 201
New medicines, discovering 116 (BR)
see also specific drugs/receptors/conditions
β-Nicotinamide–adenine dinucleotide and ryanodine receptor-sensitive Ca^{2+} channels 390
Nitric oxide (including EDRF) 18–22, 26–27
chemist's perspective 18–22
as free radical 18, 371
as redox regulator of NMDA receptors 371
vascular effects 9, 26–27, 27, 28, 29
headache/migraine and 9
ischaemic protection and 354
restenosis prevention and 403
Nitric oxide-like substance, release in brain slices 148
Nitric oxoid, proposed use of term 293 (L)
Nitrogen oxide-containing molecules, nomenclature concerning 293 (L)
Nitroprusside, sodium, as NO source 21–22
Nitrosonium ions 20
Nitrosothiols 19–20
Nitrovasodilators, controversy on definition of term 293
Nitroxide ions 20
NMDA receptors 116 (BR), 356–359, 368–374
excitotoxicity and 356–359
redox sites, as targets for selective neuronal protection 368–374
NO, *see* Nitric oxide
Nonlinear regression method 328–337, 413–417
for pK_b estimations for antagonists 328–337
spreadsheet use with 413–417
Noradrenaline, delayed myocardial protection with 352
Nucleotides, *see specific nucleotides*

O

Octopamine–tyramine receptor of *Drosophila* 235
Oesophageal 5-HT_4 receptors 394, 395
Olfactory bulb, Fos-related antigen expression 320
Oligo(deoxy)nucleotides, antisense, *see* Antisense agents
Oncogenes (cellular) as pain response markers 7
see also specific oncogenes
Opioid receptors, antisense oligodeoxynucleotides in mapping of 344–350
Orphan receptors 16
RZRβ as 81–82
Osteoblast stimulation by small fragments of parathyroid hormone 382–386
Osteoporosis therapy, small bone-building fragments of parathyroid hormone in 382–386
7-Oxo-prostacyclin, delayed cardioprotection by 352–353
Oxygen
NO reaction with 18–19
reactive species, *see* Free radicals
Oxytocin
in hypertension 245
myometrial contractility and 129

P

P-selectins and heparin 200, 201
P_2 purinoceptor 133–139
classification/subtypes 133, 170, 173
P_{2T} purinoceptor agonists, novel 179–181
P_{2U} purinoceptor 133–139
P_{2X} purinoceptor 168–174
agonist potency, order 169, 170, 171–172
original definition 168–169
P_{2Y} purinoceptor 133–139, 170
P_{2X} purinoceptors compared with 172–173
Pacing, cardiac, delayed myocardial protection by 351–352
PAF receptor antagonists, eosinophils accumulation and effects of 420
Pain
head, experimental models 5–9
mechanisms 6–7
Paralysis, hyperkalaemic periodic, Ca^{2+} channels and 47–48
Parathyroid hormone in osteoporosis therapy, small bone-building fragments of 382–386
Parkinson's disease, 5-HT_4 receptors in 392
antagonist binding 396
Partial least-squares (PLS) method in 3D-QSAR 287, 288
Patch-clamp applications and protocols 360–361
PD128907 273, 406 (L)
Peptide hormones, uterine contractility and 130
see also Neuropeptide
Peptidomimetic inhibitors of HIV-1 protease 69–70
Periodic paralysis, hyperkalaemic, Ca^{2+} channels and 47–48
Pertussis toxin and angiotensin AT_2 receptors 223, 224
Pharmaceuticals, new European regulatory procedures and directives 226–231, 409–412
Pharmacodynamics
data
analysis 143 (BR)
mathematical modelling 323 (BR)
and drug development 174–175 (BR)

Pharmacokinetics
data analysis 143 (BR)
glucocorticoid 193–196
Pharmacology and Toxicology, Annual Review (Vol. 35) 282 (BR)
Pharmacovigilance 231
Phenytoin-like anticonvulsants, mode of action 312
Phosphodiesterases
inhibitors, anti-inflammatory effects 422
isoforms, delayed cardioprotection and 353
Phospholipase A_2 activation, P_2 purinoceptors and 136
Phospholipase C activation
P_2 purinoceptors and 135, 136
in rat urinary bladder, septide-induced 366
Phospholipase D activation, P_2 purinoceptors and 136
Photoaffinity-labelling in Ca^{2+} channel blocker binding studies 48
Photochemically induced cerebral infarction 125
Photopigment molecules, retinal 158–159, 159, 160
Phylogenies, molecular, bioamine receptor family 377–381
Physiology, Annual Review of (Vol. 57) 215–216 (BR)
pK_b values for antagonists, estimation by nonlinear regression method 328–337
Plants in traditional Chinese medicine 182–187
Plasma extravasation following neurogenic inflammation 7
Platelet(s)
aggregation, novel inhibitors 179, 180–181
endothelial interactions with, P_2 purinoceptors and 134–137
see also Antiplatelet agents
Platelet-activating factor receptor antagonists, eosinophils accumulation and effects of 420
Platelet factor-4 62
Polyanions, anti-angiogenic 61
Polycations, anti-angiogenic 61
Polymerase chain reaction in neuroscience 360 (BR)
Polypeptides, anti-angiogenic 60
Polysaccharides, anti-angiogenic 60
Pore lining, Ca^{2+} channel 46–47
Positron emission tomography 117–119
Postcapillary venules of systemic microcirculation, leukocyte accumulation at 418–419
Potassium ions 1–4
channels 1–4
Ca^{2+}-dependent, NO and 26–27
in cardiac ischaemia 3
diversity 1–2
5-HT_4 receptors and 393, 397
in hypertension 3
homeostasis 3–4
see also Hyperkalaemic periodic paralysis
5α-pregnan-3α-ol-20-one and 5β-pregnan-3α-ol-20-one, $GABA_A$ receptors and 295–303
Pregnancy, preterm labour prevention 129–133
Preterm labour prevention 129–133
Progress in Drug Research (Vol. 44) 399 (BR)
Prostacyclin (PGI_2)
delayed cardioprotection by purinoceptor-mediated vasodilation and 135
Prostaglandin E_2 receptors (EP) 253–254
Prostanoids 253–256
P_2 purinoceptor-mediated vasodilation and 135
receptors, cloning 253–256
uterine contractility and 130
Protamine effects on ligand binding to muscarinic acetylcholine receptors 210
Protease inhibitors
anti-angiogenic activity 62
HIV, targeting 67
Protein(s), heparin-binding 198–199
Protein kinase C
myocardial protection and 355
P_2 purinoceptors and activation of 136
Protein tyrosine kinase inhibitors in anti-angiogenesis 63–64
Proton transport and G protein-coupled receptors 156–161
Proto-oncogenes as pain response markers 7
see also specific oncogenes
Pulmonary tissue, *see* Lung
Purinoceptors, P_2, *see* P_2 purinoceptors

Q

QSAR (quantitative structure–activity relationships) 280 (BR), 285–291
three-dimensional 285–291
Quast, Ulrich (Advisory Editorial Board) 14

R

Radical, free, *see* Free radicals
Radiolabelled ligands (in general) 151–155
binding sites 151–155
heterologous displacement experiments 154–155, 155
misinterpretation 154–155, 155
homologous displacement experiments 151–155
misinterpretation 153, 154–155
Rat
brain/CNS of 31 (BR)
global ischaemia models 124
5-HT_4 receptors 392, 396
hypertension models 239–241, 243
oesophagus, 5-HT_4 receptors 394, 395
urinary bladder, new tachykinin receptor 365–366
Reactive oxygen species, *see* Free radicals
Receptors
agonist efficacy at, *see* Agonists
allelic variations 15
in anti-angiogenesis, *see* Angiogenic factors
auto-, *see* Autoreceptors
conformation 188–189
agonist effects on 10, 188–189, 259–260 (L)
inverse agonist/antagonist effects on 10
constitutive activity in disease 11–12
diversity, cell signalling and 377
evolutionary aspects of drug interactions with 375–381
heterogeneity 235–237
inappropriate/over-expression in disease 12–13
ligands, *see* Ligands
molecular biology (in general) 322 (BR)
mutant, *see* Mutant receptors
nomenclature/classification 15
agonists/antagonists aiding 93–94
orphan, *see* Orphan receptors
promiscuity 188–192, 234–235
species homologues 15
splicing, alternative 15
subtypes, extent of discrimination between different 376–377, 406–407 (L)
3D-QSAR models 288–289
two-state model of activity/activation 83–85 (L), 89–97
practical consequences 93–94
predictions 90–92
see also specific receptors
Redox sites, NMDA receptor, as targets for selective neuronal protection 368–374
Regulatory procedures for pharmaceuticals in Europe, new 226–231, 409–412
Relaxation of vascular smooth muscle, *see* Nitric oxide; Smooth muscle
Renal system, *see* Kidney
Research
neglected factors in neuroscience and pharmacology 281 (BR)
Progress in Drug (Vol. 44) 399 (BR)
'Resistance' arteries, endothelium-derived hyperpolarizing factor studies 28
Respiratory tract, *see* Airways; Lung
Restenosis, coronary artery (following treatment) 401–404
Retina
melatonin receptors 53, 54, 55
photopigment molecules 158–159, 159, 160
Rhodopsin as secondary proton pump 158–159
Risk assessment behaviour in elevated plus maze 34
RNA splicing, *see* Splicing
RO318959 70, 70–71
Ryanodine receptor-sensitive Ca^{2+} channels 386–391
RZRβ receptor 81–82

S

Sarcoplasmic reticulum, smooth muscle, superficial buffer barrier function 98–105
Saturation binding studies of receptor subtype discrimination 376–377 (L)
SB204741 107
SB200646A 107
Schild analysis for pK_b estimations for antagonists 328, 330
compared with nonlinear regression methods 335, 336, 337
Schizophrenia
D (dopamine) receptors and 273–274, 405 (L), 406 (L)
drugs in, *see* Antipsychotic drugs
5-HT_2 receptor agonists/antagonists and 108
Sclerosis, amyotrophic lateral, Na^+ channel blockers in 314–315
Screening, dihydropyridine dehydrogenase deficiency 327
SDZ205557, anxiolysis inhibited by 395
Sea, as drug source 275–279
Sea urchin eggs, cyclic ADP-ribose-induced Ca^{2+} release 387–388
Second messenger systems, *see* Signal transduction
Seizures/convulsions
induced, Fos-related antigen expression with 318–319
prevention, *see* Anticonvulsants
see also Epilepsy
Selectins
eosinophil accumulation in allergic inflammation and 419, 420–421
heparin and 200–201
Septide-sensitive tachykinin receptors 365–367
Signal, detection in noise 282 (BR)
Signal transducers and activators of transcription (STAT) 341
Signal transduction and second messenger systems
agonists variably effecting 232–234
angiotensin AT_2 receptor (AT_2) 223–225
G protein-coupled 83, 223
antisense oligonucleotide studies of 349
receptor diversity and 377
5-HT_4 receptor, learning and memory and 393–394
insulin receptor 266
melatonin receptor 54
opioid receptor 349
P_2 purinoceptor 136–137
Single-channel recording 362 (BR)

Skeletal muscle, Ca^{2+} channels 43
Sleep disorders
  5-HT_2 receptor agonists/antagonists and 108
  melatonin and age-related 82–83
Smooth muscle
  airway, cysteinyl leukotriene effects 306
  cell proliferation, glycosaminoglycans and 202
  sarcoplasmic reticulum, superficial buffer barrier function 98–105
Smooth muscle, vascular
  hyperpolarization, *see* Endothelium-dependent hyperpolarization; Endothelium-derived hyperpolarizing factor
  P_2 purinoceptors and 135, 169
  relaxation 28, 135
    in disease 28–29
  endothelium-derived factor effecting, *see* Nitric oxide
Sodium ion
  channel blockers
    lifarazine as 141, 292 (L)
    as neuroprotective agents 141–142
  ischaemic stroke 292 (L), 309–316
  cystic fibrosis and transport of 120–121
  in hypertension (in rat models)
    accumulation 242–243
    low loading 239
Sodium nitroprusside as NO source 21–22
Software programs
  Ball and Stick 429 (SR)
  in nonlinear regression studies 413–417
  Statview 429 (SR)
Somatostatin 86–88, 110–115
  analogues 87
  in neoplastic disease, multiple actions 110–115
  receptors 86–88, 111
    classification/nomenclature 86–88, 111
Species of animals
  cerebral ischaemia studies in different 127
  5-HT_2 receptor pharmacological variations 108
Spinal trauma, Na^+ channel blockers in 313–314
Splicing (of RNA), alternative
  Ca^{2+} channel 44
  receptors 15
    prostaglandin E_2 254–255
Spreadsheets, nonlinear regression using 413–417
Statview 429 (SR)
Stenosis, coronary artery recurrent (following treatment) 401–404
Steroids
  anti-angiogenic 61
  neuroactive
    $GABA_A$ receptors and 295–303
    5-HT receptor-mediated behaviour modulated by 396
  see also Corticosteroid-binding globulin; Glucocorticoids
Streptozotocin-induced insulin deficiency and diabetes 267
Stress, from synapse to syndrome 280–281 (BR)
Striatum, 5-HT_4 receptors 392
Stroke (cerebrovascular accident), ischaemic
  acute, animal models 123–128
  Ca^{2+} channel inhibitors in 141–142
  Na^+ channel inhibitors in 141–142, 314
Structure–activity relationships, quantitative (QSAR) 280 (BR)
Substance P C-terminus analogue (septide) as NK_1 receptor agonist 365–367
Succinylcholine–tubocurarine interactions, nonlinear regression method of studying 333–334
Sum of squares (SS) in nonlinear regression 413, 414
Superoxide dismutase, adenosine effects 283, 284–285
Suprachiasmatic nucleus, melatonin receptors 81, 82
Suramin analogues 61–62
Synaptic plasticity, NMDA receptor activation and 372–373
Synonyms, pharmacological and chemical 176 (BR)

T

T cells in allergy and asthma, type 2 helper (T_H2), drugs targeting 37–38
Tachykinin receptors 31 (BR), 365–367
  NK_1 365–367
    heterogeneity 235–236, 237
    septide-sensitive 365–367
  NK_2, evolution 379
Tacrine binding to muscarinic acetylcholine receptors 210
Tension headache, experimental models 6
Ternary complex (G protein-coupled receptors) 192
  as secondary proton pump and GTP synthase 156–161
Thiols as redox regulators of NMDA receptors 370
Three-dimensional QSAR 285–291
Thrombosis, arterial, ADP and 179–181
  see also Antithrombotic compounds
Thromboxane receptor, cloning 253
Thymidine kinase gene in vascular targeted gene therapy in cancer 58
Thymidine phosphorylase inhibitors in anti-angiogenesis 63
Tocolytics in preterm labour prevention 131–132
Tone, vascular
  endothelin and 221
  endothelium-dependent hyperpolarization and 23–30
Toxic megacolon, endothelin 3 deficiency and 217, 218
Toxicology
  Annual Review of Pharmacology and (Vol. 35) 282 (BR)
  introduction to 176 (BR)
  traditional Chinese medicine natural products 185–186
Traditional Chinese medicine, progress in 182–187
Transcription factors
  AP-1 317–321
  latent cytoplasmic 341
  steroid receptors competing for 196
Transmembrane conductance regulator, cystic fibrosis 120, 137
Transmembrane domains (TMs)
  $GABA_A$ receptor 165
  5-HT_2 receptors 106
Transmitters, *see* Neurotransmitter; Neurotransmitter-gated ion channels
Trauma, *see* Injury
Tubocurarine–succinylcholine interactions, non-linear regression method of studying 333–334
Tumour(s) 110–115
  hormone-producing 13
  malignant, *see* Cancer
  somatostatin effects on 110–115
  see also specific types
Tumour necrosis factor-α in cancer gene therapy 58
Tumour-suppressor genes, anti-angiogenic activity 64
Tyrosine kinase inhibitors in anti-angiogenesis 63–64

U

U29342 72
Uridine triphosphate and P_2 purinoceptors 133
Urinary bladder of rat, new tachykinin receptor 365–366
Uterine contractions and premature labour 129–132
UTP and P_2 purinoceptors 133

V

Vanadium 265–270
  in diabetes 265–270
  toxicity 269
Vascular adhesion molecule 1 (VCAM-1), eosinophil accumulation in allergic inflammation and 419
Vascular endothelial growth factor, monoclonal antibodies to 63
Vascular headache, experimental models 7–8, 8–9
Vasculature, *see* Angiogenesis; Angiogenic factors; Arteries; Cardiovascular system; Endothelium; Microvasculature; Smooth muscle; Tone; Venules and *specific conditions/diseases/vessels and entries above/below*
Vasoactive compounds, neointimal thickening (in restenosis models) and effects of 402, 403
Vasoconstriction, chronic, restenosis and role of 402–403
Vasodilation
  endothelin receptor antagonist causing 221
  P_2 purinoceptor-mediated 135
VCAM-1, eosinophil accumulation in allergic inflammation and 419
Ventricular pacing, delayed myocardial protection by 351–352
Venules of systemic microcirculation, postcapillary, leukocyte accumulation at 418–419
Vitamin C (ascorbic acid) as redox regulator of NMDA receptors 370
Voltammetry
  fast cyclic (FCV) 145–149
VX478 73

W

World Wide Web, IUPHAR teaching site 294
Wound healing, angiogenesis in 58–59
Wu Hsing theory 183

X

Xenopus laevis melatonin receptors 55, 81
XM323 70, 72
XM412 72

Z

Zacopride and 5-HT_4 receptors 394, 395
Zileuton in asthma 305, 307

Book Review Index

B

Basara, L. R. and Montaigne, M., *Searching for Magic Bullets* 214
Behr, J-P., ed., *The Lock and Key Principle* 322
Boulton, A. A., Baker, G. B. and Adams, R. N., *Voltammetric Methods in Brain Systems. Neuromethods Vol. 27* 361
Boulton, A. A., Baker, G. B. and Walz, W., *Patch-Clamp Applications and Protocols. Neuromethods Vol. 26* 360
Bourne, D. W. A., *Mathematical Modeling of Pharmacokinetic Data* 323
Buck, S. H., ed., *The Tachykinin Receptors* 31

C

Claassen, V., *Neglected Factors in Pharmacology and Neuroscience Research* 281
Conn, P. J. and Patel, J., eds, *The Metabotropic Glutamate Receptors* 78
Cutler, N. R., Sramek, J. R. and Narong, P. K., eds, *Pharmacodynamics and Drug Development* 174

G

Gabrielsson, D. and Weiner, D., *Pharmacokinetic and Pharmacodynamic Data Analysis* 143
Goldberg, D. E. and Frishman, W. H., eds, *Beta$_2$-Adrenergic Agonism: A New Concept in Human Pharmacotherapy* 175

I

Ibelgaufts, H., *Dictionary of Cytokines* 213

K

Kubinyi, H., *QSAR: Hansch Analysis and Related Approaches* 280

P

Prous, J. R., ed., *The Year's Drug News: Therapeutic Targets 1994 edition* 143

S

Sarkar, G., *PCR in Neuroscience* 360
Sealfon, S. C., ed., *Receptor Molecular Biology* 322
Spilker, B., ed., *Medical Dictionary in Six Languages* 78
Stanford, S. C. and Salmon, P., *Stress: From Synapse to Syndrome* 280
Stonier, P. D., ed., *Discovering New Medicines* 116

T

Turner, A. J., *Neuropeptide Gene Expression* 214
Tyler, V. E., *Herbs of Choice: the Therapeutic Use of Phytomedicinals* 76

W

Walker, R. and Edwards, C., eds, *Clinical Pharmacy and Therapeutics* 76
Wolfensohn, S. and Lloyd, M., eds, *Handbook of Laboratory Animal Management and Welfare* 174

Back Issues of Elsevier Trends Journals

Back issues from 1994 and 1995 are available to our customers at the following rates. Please state which issue(s) and quantity you require, including the volume and number (or year and month).

Issues(s): _____

_____

_____

Please tick how many copies you would like below. Back issues are available in bulk at discounted rates – institutions/libraries must pay institutional rates.

Individual Rates

- ❑ Single copy £18.00/$29.00 each
- ❑ Five copies £76.50/$123.25 (includes 15% discount)
- ❑ Ten copies £135.00/$217.50 (includes 25% discount)

Institutional Rates

- ❑ Single copy £40.00/$64.00 each
- ❑ Five copies £170.00/$272.00 (includes 15% discount)
- ❑ Ten copies £300.00/$480.00 (includes 25% discount)

*Hardbound compendia of previous volumes are available to institutional subscribers. Please ask for further details.

PAYMENT METHOD:

- ❑ Personal cheque, Eurocheque, or money order made payable to **Elsevier**
- ❑ Credit card
  - ❑ Visa ❑ Mastercard ❑ American Express

Card no: _____

Expiry date: _____

Name on card: _____ Signature: _____

Total Payment sent: _____

Name: _____

Position: _____

Address: _____

_____

_____

Zip/Post Code: _____

Country: _____

Telephone: _____ Fax: _____

Please send this order with payment to:

Elsevier Trends Journals, Oxford Fulfilment Centre, PO Box 800, Kidlington, Oxford, UK OX5 1DX.
Tel: +44 1865 843300; Fax: +44 1865 843940

Elsevier Trends Journals, 660 White Plains Road, Tarrytown, NY 10591-5153, USA.
Tel: +1 (914) 524 9200; Fax: +1 (914) 333 2444. e-mail: journals@elsevier.co.uk

MAGAZINES & JOURNALS

from ELSEVIER TRENDS JOURNALS

Please send a FREE sample copy of/further information on:

- ☐ Immunology Today
- ☐ Immunology Today Online
- ☐ Molecular Medicine Today
- ☐ Parasitology Today
- ☐ Trends in Biochemical Sciences
- ☐ Trends in Biotechnology
- ☐ Trends in Cell Biology
- ☐ Trends in Ecology & Evolution
- ☐ Trends in Food Science & Technology
- ☐ Trends in Genetics
- ☐ Trends in Microbiology
- ☐ Trends in Neurosciences
- ☐ Trends in Pharmacological Sciences
- ☐ Trends in Polymer Science
- ☐ Drug Discovery Today
- ☐ Trends in Plant Science NEW

Also available

- ☐ Trends in Analytical Chemistry
- ☐ Trends in Endocrinology & Metabolism
- ☐ Trends in Cardiovascular Medicine

Name _____

Address _____

_____

_____ TA6 A02

Zip/Postcode _____ Country _____

Tel _____ Fax _____

☐ Please do not send me information from other organisations

Send, fax or 'phone your order to: Americas: Elsevier Trends Journals, [illegible] Plains Rd, Tarrytown, [illegible] 10591-5153, USA Tel: +1 (914) 524 9200 Fax: +1 (914) 333 2444
Europe/ROW: Elsevier Trends Journals, Oxford Fulfilment Centre, P.O. Box 800, Kidlington, Oxon, UK OX5 1DX Tel: +44 (0) 1865 843300 Fax: +44 (0) 1865 843940
Australia: Tel: +61 (02) 9958 4429 Fax: +61 (02) 9967 2126 Japan: Tel: +81 (3) 3836 0810 Fax: +81 (3) 3839 4344 E-mail enquiries: journals@elsevier.co.uk

ELSEVIER TRENDS JOURNALS